Abstract
Background: Drug resistance poses significant challenges in cancer therapy, often resulting in treatment failure and disease progression. Doxorubicin, a widely used anthracycline, frequently faces resistance mechanisms in cancer cells, reducing its therapeutic efficacy. This study investigated the synergistic impact of doxorubicin and BV6 on the proliferation and apoptosis of cancer cells.
Methods: Doxorubicin was combined with BV6 to enhance apoptosis in murine breast (4T1) and colorectal (CT26) cancer cells. The effects of the combined treatment on cell viability and apoptosis were assessed using the MTT assay and apoptosis assays. Additionally, reverse transcription polymerase chain reaction (RT-PCR) was used to assess the impact of co-treatment on apoptosis gene expression. Data were analyzed using GraphPad Prism 6, with a P value of less than 0.05 considered significant.
Results: The findings showed that combining doxorubicin and BV6 results in significantly higher cytotoxicity and synergistically enhances apoptosis. Co-treatment with doxorubicin and BV6 induced cell death through decreased expression of anti-apoptotic factors and elevated expression of pro-apoptotic factors, improving the cancer cell death process.
Conclusion: The cancer cells’ susceptibility to doxorubicin is enhanced by BV6. Further studies should assess the applicability and effectiveness of these interventions in vivo.